Mankind Pharma Faces Rs 341.86 Cr Tax Demand

New Delhi: Mankind Pharma Ltd on Wednesday said it has received additional tax demands, including interest, of Rs 341.86 crore from the Income Tax authority.

The company has received orders from the office of the Deputy Commissioner of Income Tax, Central Circle 29, New Delhi dated May 9, 2025 on May 13 and 14, 2025, through IT portal, raising additional tax demands, including interest, of Rs 341.86 crore, Mankind Pharma said in a regulatory filing.

The demand is on account of adjustments made and disallowance of various expenditures under different sections of the Income Tax Act, 1961, it added.

The company said it believes that “the demands under the orders are not tenable in law”, asserting it has adequate factual and legal grounds to substantiate its position and does not expect any material impact on financials or its operations due to the orders.

Mankind Pharma said it would pursue an appeal against the said orders under applicable laws.

Related Posts

Drugs & Cosmetics Rules | 60-Day Sample Testing Mandatory; Web-Host Reports: Bombay HC Orders Strict Action Against Erring Officers

The Bombay High Court (Nagpur Bench) last week expressed serious concern over repeated and systemic lapses by officers of the Drugs Department in adhering to the mandatory timelines prescribed under…

UP plans US FDA-accredited medical device testing lab

Lucknow:  In a major push to strengthen India’s medical device and pharmaceutical manufacturing ecosystem, the Uttar Pradesh govt is working on an ambitious project to establish a US FDA-accredited medical…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Drugs & Cosmetics Rules | 60-Day Sample Testing Mandatory; Web-Host Reports: Bombay HC Orders Strict Action Against Erring Officers

Drugs & Cosmetics Rules | 60-Day Sample Testing Mandatory; Web-Host Reports: Bombay HC Orders Strict Action Against Erring Officers

UP plans US FDA-accredited medical device testing lab

UP plans US FDA-accredited medical device testing lab

Patent rejected for MNC’s cancer drug, generics to follow

Patent rejected for MNC’s cancer drug, generics to follow

Zydus brings world’s first Nivolumab biosimilar to India

Zydus brings world’s first Nivolumab biosimilar to India

Dr Reddy’s set to start selling generic Ozempic in India at potentially half price

Dr Reddy’s set to start selling generic Ozempic in India at potentially half price

A total of 167 drug samples flagged as ‘not of standard quality’ in December 2025: Health Ministry

A total of 167 drug samples flagged as ‘not of standard quality’ in December 2025: Health Ministry